Soligenix (SNGX) Revenue & Revenue Breakdown

Soligenix Revenue Highlights

Latest Revenue (Y)

$839.36K

Main Segment (Y)

CiVax

Soligenix Revenue by Period

Soligenix Revenue by Year

Date	Revenue	Change
2023-12-31	$839.36K	-11.55%
2022-12-31	$948.91K	15.12%
2021-12-31	$824.27K	-65.07%
2020-12-31	$2.36M	-49.04%
2019-12-31	$4.63M	-11.67%
2018-12-31	$5.24M	-3.52%
2017-12-31	$5.43M	-48.01%
2016-12-31	$10.45M	19.16%
2015-12-31	$8.77M	24.50%
2014-12-31	$7.04M	118.45%
2013-12-31	$3.22M	2.53%
2012-12-31	$3.14M	-58.96%
2011-12-31	$7.66M	293.44%
2010-12-31	$1.95M	-30.84%
2009-12-31	$2.82M	21.89%
2008-12-31	$2.31M	83.64%
2007-12-31	$1.26M	-45.61%
2006-12-31	$2.31M	-24.80%
2005-12-31	$3.08M	208.35%
2004-12-31	$997.48K	1090.07%
2003-12-31	$83.82K	100.00%
2002-12-31	-	100.00%
2001-12-31	-	100.00%
2000-12-31	-	-100.00%
1999-12-31	$1.00	-100.00%
1998-12-31	$200.00K	100.00%
1997-12-31	$100.00K	100.00%
1996-01-31	-	-

Soligenix generated $839.36K in revenue during NA 2023, up -11.55% compared to the previous quarter, and up 16.01% compared to the same period a year ago.

Soligenix Revenue by Quarter

Date	Revenue	Change
2024-09-30	-	-100.00%
2024-06-30	$2.34K	-98.00%
2024-03-31	$117.03K	-52.20%
2023-12-31	$244.81K	87.68%
2023-09-30	$130.44K	-36.96%
2023-06-30	$206.93K	-19.54%
2023-03-31	$257.18K	-29.75%
2022-12-31	$366.07K	120.34%
2022-09-30	$166.14K	-27.34%
2022-06-30	$228.64K	21.58%
2022-03-31	$188.06K	-31.78%
2021-12-31	$275.65K	48.04%
2021-09-30	$186.20K	-13.33%
2021-06-30	$214.82K	45.55%
2021-03-31	$147.59K	-53.99%
2020-12-31	$320.79K	-47.31%
2020-09-30	$608.81K	20.49%
2020-06-30	$505.29K	-45.35%
2020-03-31	$924.55K	34.92%
2019-12-31	$685.26K	-45.39%
2019-09-30	$1.25M	-18.77%
2019-06-30	$1.54M	34.96%
2019-03-31	$1.14M	12.81%
2018-12-31	$1.01M	-26.54%
2018-09-30	$1.38M	-19.95%
2018-06-30	$1.73M	54.10%
2018-03-31	$1.12M	-13.10%
2017-12-31	$1.29M	-29.28%
2017-09-30	$1.82M	83.87%
2017-06-30	$990.97K	-25.54%
2017-03-31	$1.33M	-21.64%
2016-12-31	$1.70M	-42.60%
2016-09-30	$2.96M	-6.35%
2016-06-30	$3.16M	20.11%
2016-03-31	$2.63M	-11.49%
2015-12-31	$2.97M	-23.38%
2015-09-30	$3.88M	252.75%
2015-06-30	$1.10M	34.74%
2015-03-31	$816.29K	-57.63%
2014-12-31	$1.93M	-30.89%
2014-09-30	$2.79M	96.56%
2014-06-30	$1.42M	55.75%
2014-03-31	$910.60K	-33.97%
2013-12-31	$1.38M	341.30%
2013-09-30	$312.49K	-50.58%
2013-06-30	$632.28K	-29.77%
2013-03-31	$900.35K	12.16%
2012-12-31	$802.72K	-13.84%
2012-09-30	$931.63K	22.12%
2012-06-30	$762.85K	17.83%
2012-03-31	$647.42K	-0.88%
2011-12-31	$653.13K	-88.73%
2011-09-30	$5.80M	1328.19%
2011-06-30	$405.82K	-49.78%
2011-03-31	$808.00K	163.47%
2010-12-31	$306.67K	-64.36%
2010-09-30	$860.52K	93.53%
2010-06-30	$444.64K	32.41%
2010-03-31	$335.80K	-71.70%
2009-12-31	$1.19M	54.80%
2009-09-30	$766.64K	130.70%
2009-06-30	$332.31K	-37.34%
2009-03-31	$530.32K	-1.55%
2008-12-31	$538.64K	-11.08%
2008-09-30	$605.74K	24.06%
2008-06-30	$488.24K	-27.95%
2008-03-31	$677.64K	115.62%
2007-12-31	$314.28K	-

Soligenix generated - in revenue during Q3 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Soligenix Revenue Breakdown

Soligenix Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
CiVax	$1.50M	$1.50M	-	-	-
Contract revenue	-	$600.00K	$33.35K	-	-
Grant revenue	-	-	$790.92K	-	-
VaccinesBioDefenseMember	-	-	-	$2.24M	-
BioTherapeuticsMember	-	-	-	$117.37K	-
Bio Therapeutics	-	-	-	-	$1.23M
Vaccines Bio Defense	-	-	-	-	$3.40M

Soligenix's latest annual revenue breakdown by segment (product or service), as of Dec 23: CiVax (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18
Grant revenue	$119.37K	$117.03K	$166.14K	$228.64K	$138.06K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
CiVax	-	-	-	$1.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Public Health Solutions	-	-	-	-	$334.14K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License	-	-	-	-	-	-	$50.00K	-	-	-	-	-	-	-	-	-	-	-	-	-
Contract revenue	-	-	-	-	-	-	-	$50.00K	-	-	-	-	-	-	-	-	-	-	-	-
Government Contract	-	-	-	-	-	-	-	-	$700.00K	-	-	-	-	-	-	-	-	-	-	-
Civax	-	-	-	-	-	-	-	-	$1.50M	-	-	-	-	-	-	-	-	-	-	-
Grant	-	-	-	-	-	-	-	-	-	$214.82K	-	-	-	-	-	-	-	-	-	-
PublicHealthSolutionsMember	-	-	-	-	-	-	-	-	-	-	$147.59K	-	-	-	-	-	-	-	-	-
BioTherapeuticsMember	-	-	-	-	-	-	-	-	-	-	-	-	$64.34K	$37.28K	-	-	-	-	-	-
VaccinesBioDefenseMember	-	-	-	-	-	-	-	-	-	-	-	$320.79K	$544.47K	$468.01K	-	-	-	-	-	-
Bio Therapeutics	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$15.74K	$50.55K	$263.82K	$449.10K	$464.44K	$217.66K
Vaccines Bio Defense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$908.81K	$634.71K	$991.09K	$1.10M	$680.35K	$797.12K

Soligenix's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Grant revenue (100.00%).

Soligenix Revenue Breakdown by Country

Quarterly Revenue by Country

Country	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18	Sep 18	Jun 18	Mar 18
CiVax	$1.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Public Health Solutions	-	$334.14K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant revenue	-	-	$166.14K	$228.64K	$138.06K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License	-	-	-	$50.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Contract revenue	-	-	-	-	$50.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Government Contract	-	-	-	-	-	$700.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Civax	-	-	-	-	-	$1.50M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant	-	-	-	-	-	-	$214.82K	-	-	-	-	-	-	-	-	-	-	-	-	-
PublicHealthSolutionsMember	-	-	-	-	-	-	-	$147.59K	-	-	-	-	-	-	-	-	-	-	-	-
BioTherapeuticsMember	-	-	-	-	-	-	-	-	-	$64.34K	$37.28K	-	-	-	-	-	-	-	-	-
VaccinesBioDefenseMember	-	-	-	-	-	-	-	-	$320.79K	$544.47K	$468.01K	-	-	-	-	-	-	-	-	-
Bio Therapeutics	-	-	-	-	-	-	-	-	-	-	-	$15.74K	$50.55K	$263.82K	$449.10K	$464.44K	$217.66K	$280.13K	$276.50K	$310.52K
Vaccines Bio Defense	-	-	-	-	-	-	-	-	-	-	-	$908.81K	$634.71K	$991.09K	$1.10M	$680.35K	$797.12K	$1.10M	$1.45M	$809.26K

Soligenix's latest quarterly revenue breakdown by geography, as of Mar 23: CiVax (100.00%).

Soligenix Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ENSC	Ensysce Biosciences	$2.23M	-
ADXN	Addex Therapeutics	$1.61M	$235.00K
BXRX	Baudax Bio	$1.27M	-
SNGX	Soligenix	$839.36K	-
PALI	Palisade Bio	$250.00K	-
CNSP	CNS Pharmaceuticals	-	-
ZURA	Zura Bio	-	-
DRMA	Dermata Therapeutics	-	-
ERYP	PHAXIAM Therapeutics	-	-
ATXI	Avenue Therapeutics	-	-
CFRX	ContraFect	-	-
PHIO	Phio Pharmaceuticals	-	-
IMMX	Immix Biopharma	-	-
ALLR	Allarity Therapeutics	-	-
EFTR	eFFECTOR Therapeutics	-	-
WINT	Windtree Therapeutics	-	-

SNGX Revenue FAQ

What is Soligenix’s yearly revenue?

Soligenix's yearly revenue for 2023 was $839.36K, representing a decrease of -11.55% compared to 2022. The company's yearly revenue for 2022 was $948.91K, representing an increase of 15.12% compared to 2021. SNGX's yearly revenue for 2021 was $824.27K, representing a decrease of -65.07% compared to 2020.

What is Soligenix’s quarterly revenue?

Soligenix's quarterly revenue for Q3 2024 was $0, a -100.00% decrease from the previous quarter (Q2 2024), and a -100.00% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $2.34K, a -98.00% decrease from the previous quarter (Q1 2024), and a -98.87% decrease year-over-year (Q2 2023). SNGX's quarterly revenue for Q1 2024 was $117.03K, a -52.20% decrease from the previous quarter (Q4 2023), and a -54.49% decrease year-over-year (Q1 2023).

What is Soligenix’s revenue growth rate?

Soligenix's revenue growth rate for the last 3 years (2021-2023) was 1.83%, and for the last 5 years (2019-2023) was -81.87%.

What are Soligenix’s revenue streams?

Soligenix's revenue streams in c 23 are CiVax

What is Soligenix’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Soligenix was CiVax. This segment made a revenue of $1.5M, representing 100.00% of the company's total revenue.